RESEARCH PAPER
Treatment adherence and short-term outcomes of smoking cessation outpatient clinic patients
 
More details
Hide details
1
Department of Chest Diseases, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey
2
Department of Public Health, Süleyman Demirel University, Isparta, Turkey
3
Department of Social Services, Faculty of Economics and Administrative Sciences, Burdur Mehmet Akif Ersoy University, Burdur, Turkey
4
Department of Psychiatric Nursing, School of Health Science, Çoruh University, Artvin, Turkey
CORRESPONDING AUTHOR
Dilek Karadoğan   

Department of Chest Diseases, Faculty of Medicine, Recep Tayyip Erdoğan University, 05000 Rize, Turkey
Publish date: 2018-08-30
 
Tob. Induc. Dis. 2018;16(August):38
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Previous studies have shown that adherence to treatment is fundamental to success in smoking cessation. However, smoking cessation medication regimens are limited significantly by the struggle to adhere to them. This study was conducted to evaluate the factors associated with treatment adherence and quitting success in a group of patients that applied to our smoking cessation outpatient clinic (SCC).

Methods:
Patients that applied to SCC between April 2015 and December 2016 who were evaluated, found suitable for smoking cessation interventions and started pharmacological treatment were included in this study. Only those who could be reached by phone three months after their first application became participants. Those who had used the prescribed treatment for at least 30 days were grouped as treatment-adherent.

Results:
In total, data for 346 patients were evaluated. Mean (±SD) age was 44.3±13.9 years; most of them were male (63%), primary school graduated (36.1%), self-employed (43.7%), and had no comorbid diseases (71%). Bupropion was started in 52% of the patients, that rate was 35.8% for varenicline and 12.1% for a combination of the nicotine patch and gum. Mean days for treatment use was 20.9±18.5; 59% of the patients were non-adherent to their treatment and 51.7% had only one control visit number. Adverse reactions due to treatment were recorded in 25% of participants, and at their third month 37.9% of them had quit smoking. In multivariate logistic regression analysis, increase in control visit number, absence of adverse reaction, and varenicline use, were each associated with higher treatment adherence (p<0.001) and only being in the treatment-adherent group was associated with quit success (OR=3.01, 95% CI: 1.88–4.81, p=0.001).

Conclusions:
This study showed that most patients did not use their prescribed SC treatments adequately; a main factor that affects quit success is treatment adherence. There is a need for closer monitoring and follow-up to ensure adequate use of treatment of patients.

 
REFERENCES (29)
1. World Health Organization. Tobacco 2015. http://www.who.int/mediacentre.... Accessed November 14, 2015.
2. Baker CL, Flores NM, Zou KH, Bruno M, Harrison VJ. Benefits of quitting smoking on work productivity and activity impairment in the United States, the European Union and China. Int J Clin Pract. 2017;71(1). doi:10.1111/ijcp.12900
3. Quitting smoking: the benefits. Breathe. 2017;13(3):263-265. doi:10.1183/20734735.ELF133
4. Çakmakçı Karadoğan D, Önal Ö, Say Şahin D, Yazıcı S, Kanbay Y. Evaluation of school teachers' sociodemographic characteristics and quality of life according to their cigarette smoking status: a cross-sectional study from the eastern Black Sea region of Turkey. Tuberk Toraks. 2017;65(1):18-24. doi:10.5578/tt.48618
5. El-Khoury Lesueur F, Bolze C, Melchior M. Factors associated with successful vs. unsuccessful smoking cessation: Data from a nationally representative study. Addict Behav. 2018;80:110-115. doi:10.1016/j.addbeh.2018.01.016
6. Zhu S, Melcer T, Sun J, Rosbrook B, Pierce JP. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med. 2000;18(4):305-311. doi:10.1016/s0749-3797(00)00124-0
7. World Health Organization. Tobacco Control Country Profiles 2014. http://www.tobaccocontrollaws..... Accessed May 21, 2018.
8. Bilir N, Özcebe H. Tobacco control activities in Turkey. Turk J Public Health. 2013;11(2).
9. Kunt Uzaslan E, Örsel O, Demir T. Türkiye’de Sigara Bıraktırma Poliklinikleri. http://www.toraks.org.tr/userf.... Accessed May 21, 2018.
10. Elbek O, Kılınç O, Aytemur ZA, et al. Tobacco Control in Turkey. Turk Thorac J. 2015;16:141-50. doi:10.5152/ttd.2014.3898
11. Çelik İ, Yüce D, Hayran M, et al. Nationwide Smoking Cessation Treatment Support Program--Turkey project. Health Policy. 2015;119(1):50-56. doi:10.1016/j.healthpol.2014.11.017
12. Hays JT, Leischow SJ, Lawrence D, Lee TC. Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. Nicotine Tob Res. 2010;12(6):574-581. doi:10.1093/ntr/ntq047
13. Balmford J, Borland R, Hammond D, Cummings KM. Adherence to and reasons for premature discontinuation from stop-smoking medications: datafrom the ITC Four-Country Survey. Nicotine Tob Res. 2011;13(2):94-102. doi:10.1093/ntr/ntq215
14. Schlam TR, Cook JW, Baker TB, et al. Can we increase smokers' adherence to nicotine replacement therapy and does this help them quit? Psychopharmacology. 2018;235(7):2065-2075. doi:10.1007/s00213-018-4903-y
15. Liberman JN, Lichtenfeld MJ, Galaznik A, et al. Adherence to varenicline and associated smoking cessation in a community-based patient setting. J Manag Care Pharm. 2013;19(2):125-131. doi:10.18553/jmcp.2013.19.2.125
16. Grandi SM, Eisenberg MJ, Joseph L, O'Loughlin J, Paradis G, Filion KB. Cessation treatment adherence and smoking abstinence in patients after acute myocardial infarction. Am Heart J. 2016;173:35-40. doi:10.1016/j.ahj.2015.12.003
17. 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008;53(9):1217-1222.
18. Pacek LR, McClernon FJ, Bosworth HB. Adherence to pharmacological smoking cessation interventions: A literature review and synthesis of correlates and barriers. Nicotine Tob Res. 2017. doi:10.1093/ntr/ntx210
19. Figueiró LR, Barros HM, Ferigolo M, Dantas DC. Assessment of factors related to smokers' adherence to a short-term support group for smoking cessation: a longitudinal study in a developing country. Trends Psychiatry Psychother. 2017;39(1):19-28. doi:10.1590/2237-6089-2016-0041
20. Benli AR, Erturhan S, Oruc MA, Kalpakci P, Sunay D, Demirel Y. A comparison of the efficacy of varenicline and bupropion and an evaluation of the effect of the medications in the context of the smoking cessation programme. Tob Induc Dis. 2017;15(10). doi:10.1186/s12971-017-0116-0
21. Patnode CD, Henderson JT, Thompson JH, Senger CA, Fortmann SP, Whitlock EP. Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessationin Adults, Including Pregnant Women: A Review of Reviews for the U.S. Preventive Services Task Force [Internet]. Report No.: 14-05200-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015.
22. Önür ST, Uysal MA, İliaz S, et al. Does Short Message Service Increase Adherence to Smoking Cessation Clinic Appointments and Quitting Smoking? Balkan Med J. 2016;33(5):525-531. doi:10.5152/balkanmedj.2016.151610
23. Trofor AC, Man MA, Marginean C, Dumitru F, Trofor L. Smoking cessation for free: outcomes of a study of three Romanian clinics. Open Med. 2016;11(1):605-610. doi:10.1515/med-2016-0098
24. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55. doi:10.1001/jama.296.1.47
25. Rosen LJ, Galili T, Kott J, Goodman M, Freedman LS. Diminishing benefit of smoking cessation medications during the first year: a meta-analysis of randomized controlled trials. Addiction. 2018;113(5). doi:10.1111/add.14134
26. World Health Organization. Toolkit for delivering the 5A's and 5R's brief tobacco interventions in primary care. Geneva, Switzerland: World Health Organization, 2014.
27. Hollands GJ, McDermott MS, Lindson-Hawley N, Vogt F, Farley A, Aveyard P. Interventions to increase adherence to medications for tobacco dependence. Cochrane Database Syst Rev. 2015;(2):CD009164. doi:10.1002/14651858.cd009164.pub2
28. Baker TB, Piper ME, Stein JH, et al. Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. JAMA. 2016;315(4):371-379. doi:10.1001/jama.2015.19284
29. Kim Y, Cho WK. Factors Associated with Successful Smoking Cessation in Korean Adult Males: Findings from a National Survey. Iran J Public Health. 2014;43(11):1486-1496.
eISSN:1617-9625